Does Dordaviprone Interact with Mao Inhibitors?
CDI records a major classification for Dordaviprone and Mao Inhibitors. The stored summary is: Strong CYP3A4 inhibitors increase dordaviprone exposure, which may increase the risk of MODEYSO-related adverse reactions. Avoid concomitant use or reduce MODEYSO dose if unavoidable. The mechanism involves dordaviprone is a cyp3a4 substrate; inhibitors increase its exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Dordaviprone Class
- Protease Activator
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Dordaviprone is a CYP3A4 substrate; inhibitors increase its exposure
What To Tell Your Doctor or Pharmacist
If you are taking Dordaviprone and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider